拉米夫定胸腺肽治疗慢性乙型肝炎临床研究

目的　观察拉米夫定联合胸腺肽治疗慢性乙型肝炎的疗效。 方法　 分别为A组贺普丁加迪赛联合组 30例 ,B组单用贺普丁组 2 5例。疗程 6个月。 结果　A组与B组HBVDNA阴转率分别为 93 3%(2 8/ 30 )、92 %(2 3/ 2 5 ) ,P >0 0 5。抗HBe阳转率分别为 2 0 %(6 / 30 )、8%(2 / 2 5 ) ,P >0 0 5。Tbil复常率分别为6 3 3%(19/ 30 )、5 2 %(13/ 2 5 ) ,P <0 0 5。ALT复常率分别为 86 7%(2 6 / 30 )、6 4%(16 / 2 5 ) ,P <0 0 5差异显著。HBeAg阴转率 6 0 %(18/ 30 )、2 4%(6 / 2 5 ) ,P <0 0 1差异显著。 结论　 贺普丁联合迪赛治疗慢性乙型肝炎疗效较好 ,有临床应用价值。

Clinical Study of Lamivudine and Thymulin Treating Chronic Hepatitis B

Objective To study the curative effect of lamivudine and thymulin on the treatment of chronic hepatitis B.Methods 55 cases with chroonic hepatitis B were divided into group A (30 cases) and group B(25 cases).Lamivudine and thymus were adopted in group A.Only Lamivudine was adopted in group B.The treatment of each group lasted 6 months.Results In group A and B,the negative transforming rate of HBV DNA,were 93.3%(28/30),92%(23/25).(P>0.05);the positive transforming rate of anti HBe were 20%(6/30),8%(2/25).(P>0.05);the ALT recovery rate were 86.7%(26/30),64% (6/25).(P<0.05);the Tbil recovery rate were 63.3%(19/30),52%(13/25).(P<0.05)the negative transforming rate of HBeAg were 60%(18/30),24%(6/25)(P<0.01).Conclusion the lamivudine used together with thymus has better curative effect in treating hepatitis B.